**Core Concept:** Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily for the treatment of estrogen receptor-positive breast cancer and as an adjuvant therapy to reduce the risk of recurrence.

**Why the Correct Answer is Right:** Tamoxifen is a selective estrogen receptor modulator that blocks the action of estrogen on estrogen receptors, thereby reducing breast cancer risk. While tamoxifen is beneficial in preventing breast cancer in high-risk patients, it does have some side effects, including an increased risk of developing endometrial malignancies due to its estrogen-agonist activity in the endometrium.

**Why Each Wrong Option is Incorrect:**

A. Tamoxifen does not increase the risk of lung cancer, which is a separate malignancy unrelated to estrogen receptors.

B. Tamoxifen does not increase the risk of prostate cancer, another unrelated malignancy.

C. Tamoxifen does not increase the risk of hematologic malignancies, as these cancers are not directly related to estrogen receptor modulation.

D. Tamoxifen does not increase the risk of ovarian cancer, which is unrelated to estrogen receptors and tamoxifen's mechanism of action.

**Clinical Pearl:** The increased risk of endometrial malignancies with tamoxifen highlights the importance of closely monitoring patients on tamoxifen therapy for symptoms of endometrial cancer, such as abnormal vaginal bleeding or pelvic pain. This underscores the importance of regular gynecological examinations for these patients to detect endometrial cancer at an early stage and manage the risk appropriately.

**Correct Answer:** D. Tamoxifen increases the risk of uterine (endometrial) malignancies due to its estrogen-agonist activity in the endometrium.